H.C. Wainwright analyst Douglas Tsao has reiterated their bullish stance on ARGX stock, giving a Buy rating yesterday.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Douglas Tsao has given his Buy rating due to a combination of factors related to Argenx Se’s recent advancements in their neuromuscular treatment pipeline. The company has announced the progression of ARGX-119 into a registrational study for congenital myasthenic syndromes (CMS), marking it as the third molecule to reach late-stage clinical development. This decision follows positive topline data from a Phase 1b study, which showed favorable safety, tolerability, and consistent improvements in efficacy scores among patients.
Furthermore, the study demonstrated the effectiveness of Argenx’s SIMPLE Antibody platform technology, reinforcing confidence in their innovative approach to antibody development. The ongoing natural history study in CMS patients is expected to provide valuable real-world data, enhancing the robustness of their clinical findings. Additionally, with a Phase 2a study for ARGX-119 in amyotrophic lateral sclerosis (ALS) underway, Argenx is poised to expand its therapeutic reach, potentially making ARGX-119 the first approved treatment targeting DOK7-CMS, an ultra-rare neuromuscular disorder.
In another report released yesterday, Bank of America Securities also maintained a Buy rating on the stock with a $804.00 price target.